z-logo
open-access-imgOpen Access
Clinical Features and Course of Systemic Onset Juvenile Rheumatoid Arthritis
Author(s) -
Jieun Kim,
SoYoung Bang,
Sang Bong Ahn,
Keum Nam Rim,
Hyun Soo Kim,
Wan Sik Uhm,
TaeHwan Kim,
Jae Bum Jun,
SangCheol Bae,
DaeHyun Yoo
Publication year - 2007
Publication title -
the journal of the korean rheumatism association
Language(s) - English
Resource type - Journals
ISSN - 1226-8070
DOI - 10.4078/jkra.2007.14.4.331
Subject(s) - medicine , thrombocytosis , leukocytosis , rheumatoid factor , juvenile rheumatoid arthritis , anti nuclear antibody , hydroxychloroquine , rash , arthritis , rheumatology , rheumatoid arthritis , gastroenterology , surgery , disease , immunology , antibody , autoantibody , platelet , covid-19 , infectious disease (medical specialty)
Objective: Juvenile rheumatoid arthritis (JRA) is classified as polyarticular, oligoarticular, and systemic onset type by clinical symptoms presented during first six months. This study was performed to investigate the clinical features and course of systemic onset JRA. Methods: We performed a retrospective study for patients who were diagnosed as JRA between March 2000 and March 2006 according to the JRA criteria of the International League of Association for Rheumatology (ILAR). Results: Of the 216 JRA patients, 33 patients (11 male/ 22 female) were systemic onset type. Because of insufficient data, 6 patients were excluded. Chief complaints at the time of diagnosis were fever (81.5%) and arthralgia (77.7%). During the disease course, all patients manifested fever and arthritis, rash (59.2%) and splenomegaly (22.2%) also occurred. Most patients had symmetric (81.5%) arthritis, and involved more than five joints (59.3%) including knee and wrist. Anemia, leukocytosis, and thrombocytosis were common laboratory abnormalities. Almost all patients had elevated level of C-reactive protein and erythrocyte sediment rate. Some patients had positive results about immunologic marker such as rheumatoid factor (3.8%), antinuclear antibody (57.7%), and antiperinuclear factor (9.5%). Therapeutic regimens included glucocor

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom